re,read why,add it all together now
READ IT ALL LEMONYMimotopes signs three year Multi-Million Dollar Global Peptide Deal 14th February, 2006 PharmAust Limited (ASX:PAA), through its wholly owned subsidiary Mimotopes Pty Ltd, has today signed a new three year contract with global biotechnology group Invitrogen Corporation (NASDAQ:IVGN) to exclusively supply research-grade peptides to Invitrogen's worldwide customer base.
This new three-year contract sees Mimotopes become the sole and exclusive provider of research-grade peptides worldwide (excluding Japan) to Invitrogen, which conducts business in more than 70 countries around the world - placing its products in nearly every major laboratory in the world.
The deal gives Mimotopes unparalleled access to the US$500M and rapidly growing research grade peptide market and provides a firm foundation for Mimotopes to achieve its goal of securing 5% of this global market.
PharmAust Managing Director Dr. Paul D'Sylva said: "This contract will cement Mimotopes position as the pharmaceutical industry's Austalian partner of choice for research grade peptides."
"Mimotopes is now able to expand its production capacity locally as well as enhance its production capabilities offshore by way of strategic out-sourcing arrangements."
With a market capitalisation of US$4 billion, California-based Invitrogen provides essential life science technologies for disease research and drug discovery to pharmaceutical and biotechnology companies, as well as research institutions.
Dr. Nicholas Ede joins Mimotopes 30th January, 2006 Mimotopes is pleased to announce the appointment of Dr. Nicholas Ede as R&D Director. Dr. Ede will also fill the role of Business Development Manager for PharmAust Limited subsidiary Epichem.
Commencing 30 January, 2006, Dr. Ede will drive the innovative direction of Mimotopes through both in-house programs and also by actively in-licensing opportunities in peptide science. This will also include the active in-licencing of pre-clinical peptide therapeutic opportunities.
Dr. Ede joins Mimotopes from his previous position as Chief Operating Officer at Eqitx where he managed the pre-clinical drug development program of Eqitx's subsidiary company Zingotx.
Mimotopes and Genzyme Corporation join forces in a global Strategic Alliance Agreement 27th January, 2006 PharmAust Limited (ASX:PAA) is pleased to announce that its wholly owned subsidiary, Mimotopes Pty Ltd, and Genzyme Corporation have signed an exclusive and global Strategic Alliance Agrement to provide a total suite of peptide products and services to both companies' significant customer bases.
The agreement, which commences on February 1, 2006, will see Mimotopes join forces with Genzyme Pharmaceuticals, a business unit of Genzyme Corporation focused in the development and manufacture of peptide and lipid products and technologies, to provide a full suite of products and services for research use to therapeutic grade peptides. The alliance will offer customers of both companies an integrated 'one-stop-shop' opportunity from the laboratory to the clinic, by way of of an exclusive referral agreement. Mimotopes will supply customers with research grade peptides and related services up to the point of lead candidate identification in pre-clinical applications and Genzyme will supply customers with identified lead candidate peptides for pre-clinical applications through to clinical and therapeutic grade peptides and related services.
The Genzyme Pharmaceuticals/Mimotopes co-branded peptide services will be made available to both companies' customer bases, with Mimotopes' range of research-grade and pre-clinical peptides available to Genzyme Pharmaceuticals' significant global customer base and distribution network. The alliance will also provide Genzyme's clinical customers access to Mimotopes' expertise in the production of pre-clinical grade peptides, utilising its proprietary technology and patented synthesis platform.
EqiTx and Mimotopes sign partnering deal 18th September, 2005 Eqitx (ASX:EQX) and PharmAust (ASX:PAA) subsidiary Mimotopes have signed a partnership deal to jointly develop new targets for therapeutic or diagnostic approaches.
Both companies specialise in novel small molecule and peptide therapeutics drug discovery and development. "There have been some synergies with PharmAust and Eqitx for quite some time" said Eqitx CEO Sue MacLeman
Mimotopes has been making Eqitx's peptide vaccines for testing and before Mimotopes was acquired by PharmAust, the company did a lot of work on Eqitx's pain compounds, running part of Eqitx's medicinal chemistry program. Mimotopes managing director Dr. Paul D'Sylva was also involved in setting up Eqitx and sat on its first scientific advisory board, said MacLeman.
We're quite comfortable working with them and understand their structure" she said. "Rather than do a corporate consolidation we thought we could do a collaboration and see how that added value to both groups.
The two companies will have an equal share in any income resulting from the commercialisation of targets developed and will be developing compounds in areas not currently covered by existing programs. "Ultimately, the collaboration could form a new company that could be spun out in other areas" said MacLeman.
"While the specific areas targeted by the collaboration - which begins immediately - have not been disclosed, the two companies will be developing drug candidates in the general are of chronic diseases and ageing" said MacLeman.
Phylogica and PharmAust sign partnering deal to expedite development of improved peptide-based therapeutics. 15th August, 2005 Phylogica Ltd (ASX:PYC) and Mimotopes Pty Ltd, a wholly owned subsidiary of PharmAust Ltd (ASX:PAA), have signed a partnering deal to work together using their complementary technology platforms to develop next generation peptide drugs.
Phylogica's Phylomer® technology comprises unique peptides (protein parts) that block the unwanted and harmful interactions between proteins involved in a range of common diseases, including stroke, diabetes and asthma.
The Synphase™ platform owned by Mimotopes incorporates complementary technology that will enable the rapid production and optimisation of large libraries of the Phylomers identified by Phylogica as potential therapeutics.
Peptides are becoming increasingly important in the area of therapeutics, with a variety of new peptide drugs under development for cancer, pain, viral infections, diabetes and a host of endocrinological and neurological disorders. The peptide therapeutic market is currently estimated at US$1b and growing at an average annual rate of 40% (Business Communications Company, 2005).
Managing Director of Mimotopes, Dr Paul D’Sylva, said: “This Agreement aligns with our strategy of leveraging the position of Mimotopes as a leader in custom peptide synthesis for therapeutic applications through the formation of joint ventures with high quality drug discovery companies. This partnership with Phylogica positions Mimotopes well to participate in this large and growing market.”
According to Dr D’Sylva, recent developments in several technologies related to the synthesis, screening, stabilisation and modification of peptides will facilitate the transit of peptide-based molecules to clinical trials and on to the market.
“This deal with Mimotopes fits with Phylogica’s approach of forming strategic partnerships that will increase the commercial and therapeutic value of our peptide drug candidates through the adoption of new technologies,” Dr Stewart Washer, Chief Executive Officer of Phylogica, said.
“We look forward to creating, with the aid of Mimotopes’ technology, the next generation of Phylomer® drug candidates with improved therapeutic profiles.”
Phylogica (www.phylogica.com) was founded and incorporated in 2001 to commercialise its proprietary drug discovery technologies, developed over six years through a collaboration between the Telethon Institute for Child Health Research in Perth (www.ichr.uwa.edu.au) and the Fox Chase Cancer Center (www.fccc.edu) in Philadelphia, United States. The founding research institutes have assigned their rights to the technologies into Phylogica in exchange for shareholdings in the company.
About Phylomers
Phylomers® are stable fragments of naturally-occurring proteins (ie peptides) that can bind to target proteins and inactivate them as a result. Phylomers® can be selected for activity against specific proteins. Phylogica's proprietary Phylomer® Libraries consist of collections of millions of Phylomers® and represent a source of drug leads that double as agents for the validation of potential new targets.
About Mimotopes
Mimotopes is a recognised leader in the development of pre-clinical peptides for biological and pharmaceutical applications. Established in Melbourne, Australia in 1989, Mimotopes has sales offices and distribution channels in the US, UK, Europe, Japan, India and China. Mimotopes’ proprietary technologies in solid phase synt hesis, scavenging applications and biomolecular capture and immobilisation, coupled with the extensive experience and in depth know-how of its highly trained staff, have made it one of the global leaders in its field.
Dr. Paul D'Sylva Joins Mimotopes as Managing Director 11th July, 2005 Mimotopes is pleased to announce the appointment of Dr. Paul D'Sylva as Managing Director.
Commencing July 1, 2005, Dr. D'Sylva will focus on delivering earnings growth through exploiting Mimotopes' considerable client base and expanding into new markets in its core business of peptide synthesis and SynPhase technology.
Dr. D'Sylva joins Mimotopes from his position as Director of Research and Development at Murdoch University, where he led the development of a number of successful research and commercialisation joint ventures.
Dr. D'Sylva said: "I am thrilled at this opportunity to lead Mimotopes in an executive capacity through this new and exciting phase of it’s development as part of the PharmAust group of companies.
PharmAust Chemistry Ltd acquires Mimotopes 19th April, 2005 We are pleased to announce that Mimotopes has been acquired by PharmAust Chemistry Ltd. PharmAust Chemistry is a wholly owned subsidiary of PharmAust Ltd (PAA) (www.pharmaust.com).
This acquisition allows Mimotopes to continue as a leading supplier of custom peptides, peptide libraries and peptide related products to all our valued and customers.
Mimotopes will also continue to market its unique SynPhase range of products for solid phase combinatorial chemistry and drug discovery.
We are very pleased by this change in our ownership and trust that you will share in our excitement. We look forward to continuing our tradition of providing great service and high quality products to the scientific community.
For a technical evaluation or quote please contact Mimotopes through your local office or distributors (http://www.mimotopes.com/contact/distrib.html), or by using the peptides order form (http://www.mimotopes.com/ordering/ordform.html).
Mimotopes secures license from Molecular Probes to supply labelled peptides 22nd March, 2004 Mimotopes is pleased to announce the availability of peptides labelled with fluorescent dyes from the Molecular Probes range of proprietary fluorophores, including the unique Alexa Fluor® and BODIPY® dye series, as well as the Texas Red® and Oregon Green® dyes. Mimotopes has secured a license from Molecular Probes to supply such labelled peptides for non-commercial (research) purposes. A technical evaluation and a quote for labelled peptides can be requested by contacting Mimotopes through your local office or distributors, or by using the the peptides order form.
DPI Enters into a License and Development Agreement with Mimotopes Pty. Ltd. 25th November, 2002 SAN DIEGO, Nov. 25, 2002 /PRNewswire-FirstCall via COMTEX/ -- Discovery Partners International, Inc. (NASDAQ: DPII) and Mimotopes Pty Ltd, a subsidiary of Fisher Scientific International Inc. (NYSE: FSH), announced today that they have entered into a multi-year agreement under which Discovery Partners will licence to Mimotopes certain of it’s intellectual property rights and will appoint Mimotopes as a nonexclusive, worldwide distributor of certain products in Discovery Partners’ IRORI combinatorial chemistry instruments product line. Financial terms of the arrangements were not released. Full Article
Mimotopes Recognized for Contribution to Nara Conference 14th June, 2002 A press release from Ausbiotech and SDA Biotech recognized Mimotopes' contribution to the organization of the recent successful
PYC Price at posting:
0.0¢ Sentiment: Buy Disclosure: Not Held
(20min delay)